Literature DB >> 1675371

Bone-marrow transplantation for congenital erythropoietic porphyria.

L Kauffman1, D I Evans, R F Stevens, C Weinkove.   

Abstract

Congenital erythropoietic porphyria, a disorder of haem synthesis, is caused by uroporphyrinogen III synthase deficiency in bone-marrow normoblasts. Uroporphyrins and coproporphyrins accumulate and cause oxidative damage to cells exposed to sunlight. Uroporphyrin overproduction was greatly reduced and skin changes reversed in a girl who received a bone-marrow graft from an HLA-identical sibling at 10 years of age. The patient died 11 months after transplantation because of severe progressive pneumonitis and encephalopathy associated with cytomegalovirus infection, but the encouraging response up to 8 months after engraftment indicates a possible benefit of bone-marrow transplantation in the treatment of this rare but usually fatal inherited disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675371     DOI: 10.1016/0140-6736(91)93198-i

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  [Congenital erythropoietic porphyria : An update].

Authors:  C Wenner; N J Neumann; J Frank
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

Review 2.  Erythropoietic protoporphyria.

Authors:  T M Cox
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

3.  Feline congenital erythropoietic porphyria: two homozygous UROS missense mutations cause the enzyme deficiency and porphyrin accumulation.

Authors:  Sonia Clavero; David F Bishop; Urs Giger; Mark E Haskins; Robert J Desnick
Journal:  Mol Med       Date:  2010-05-12       Impact factor: 6.354

4.  Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria.

Authors:  F Mazurier; F Moreau-Gaudry; S Salesse; C Barbot; C Ged; J Reiffers; H de Verneuil
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

5.  Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease).

Authors:  Sophie Dupuis-Girod; Véronique Akkari; Cécile Ged; Claire Galambrun; Kamila Kebaïli; Jean-Charles Deybach; Alain Claudy; Lucette Geburher; Noël Philippe; Hubert de Verneuil; Yves Bertrand
Journal:  Eur J Pediatr       Date:  2004-11-20       Impact factor: 3.183

Review 6.  Porphyrias: animal models and prospects for cellular and gene therapy.

Authors:  H de Verneuil; C Ged; S Boulechfar; F Moreau-Gaudry
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

7.  Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

Authors:  Elodie Robert-Richard; François Moreau-Gaudry; Magalie Lalanne; Isabelle Lamrissi-Garcia; Muriel Cario-André; Véronique Guyonnet-Dupérat; Laurence Taine; Cécile Ged; Hubert de Verneuil
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

8.  Bone marrow transplants in genetic diseases.

Authors:  J R Hobbs
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

Review 9.  Congenital erythropoietic porphyria: Recent advances.

Authors:  Angelika L Erwin; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2018-12-27       Impact factor: 4.797

10.  Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors.

Authors:  Aurélie Bedel; Miguel Taillepierre; Véronique Guyonnet-Duperat; Eric Lippert; Pierre Dubus; Sandrine Dabernat; Thibaud Mautuit; Bruno Cardinaud; Catherine Pain; Benoît Rousseau; Magalie Lalanne; Cécile Ged; Yann Duchartre; Emmanuel Richard; Hubert de Verneuil; François Moreau-Gaudry
Journal:  Am J Hum Genet       Date:  2012-07-13       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.